Login to Your Account

Aeterna Zentaris Slides on Perifosine Miss in Myeloma

By Staff Reports

Monday, March 11, 2013
Shares of Aeterna Zentaris dropped 22.5 percent Monday after a data safety monitoring board (DSMB) said it was unlikely a Phase III study testing PI3/Akt inhibitor perifosine in multiple myeloma would hit its endpoints.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription